EUVIMEDEUVIMED entdecken
Crossref

Vaporized mebufotenin leads to improvement in treatment‐resistant depression

The Brown University Psychopharmacology Update · 2026-08 · 37 (8) · 1-5

DOI: 10.1002/pu.31471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 28.06.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An individualized one‐day dosing regimen of a vaporized formulation of the psychedelic mebufotenin (5‐methoxy‐ N,N ‐dimethyltryptamine; 5‐MeO‐DMT) was more effective than placebo in improving depressive symptoms in adults with treatment‐resistant depression, a Phase 2b trial has found. No serious treatment‐emergent adverse events were reported during the 7‐day study. Results were published online March 2, 2026 in JAMA Psychiatry .

Zitieren

APA

(2026). Vaporized mebufotenin leads to improvement in treatment‐resistant depression. The Brown University Psychopharmacology Update, 37(8), 1-5. https://doi.org/10.1002/pu.31471

Vancouver

Vaporized mebufotenin leads to improvement in treatment‐resistant depression. The Brown University Psychopharmacology Update. 2026;37(8):1-5. doi:10.1002/pu.31471

BibTeX
@article{euvimed2026,
  title = {Vaporized mebufotenin leads to improvement in treatment‐resistant depression},
  journal = {The Brown University Psychopharmacology Update},
  year = {2026},
  volume = {37},
  number = {8},
  pages = {1--5},
  doi = {10.1002/pu.31471}
}
Kostenlos starten →